GEN Financial Management INC. Invests $266,000 in Boston Scientific Co. (NYSE:BSX)

GEN Financial Management INC. acquired a new stake in shares of Boston Scientific Co. (NYSE:BSX) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm acquired 2,979 shares of the medical equipment provider’s stock, valued at approximately $266,000.

Several other large investors also recently added to or reduced their stakes in the stock. Optas LLC increased its holdings in Boston Scientific by 9.2% during the 4th quarter. Optas LLC now owns 3,878 shares of the medical equipment provider’s stock worth $346,000 after purchasing an additional 327 shares during the period. GDS Wealth Management increased its stake in shares of Boston Scientific by 269.2% during the fourth quarter. GDS Wealth Management now owns 21,596 shares of the medical equipment provider’s stock valued at $1,929,000 after buying an additional 15,747 shares during the period. Jennison Associates LLC increased its stake in shares of Boston Scientific by 27.1% during the fourth quarter. Jennison Associates LLC now owns 1,942,955 shares of the medical equipment provider’s stock valued at $173,545,000 after buying an additional 414,774 shares during the period. Resonant Capital Advisors LLC raised its holdings in shares of Boston Scientific by 9.0% in the fourth quarter. Resonant Capital Advisors LLC now owns 4,345 shares of the medical equipment provider’s stock valued at $388,000 after acquiring an additional 358 shares in the last quarter. Finally, Catalina Capital Group LLC lifted its stake in Boston Scientific by 4.0% in the fourth quarter. Catalina Capital Group LLC now owns 6,140 shares of the medical equipment provider’s stock worth $548,000 after acquiring an additional 236 shares during the period. 89.07% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Boston Scientific

In related news, EVP John Bradley Sorenson sold 4,119 shares of the firm’s stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $90.02, for a total transaction of $370,792.38. Following the completion of the transaction, the executive vice president now owns 35,319 shares of the company’s stock, valued at $3,179,416.38. This trade represents a 10.44 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Arthur C. Butcher sold 14,010 shares of the company’s stock in a transaction on Monday, November 25th. The shares were sold at an average price of $89.27, for a total transaction of $1,250,672.70. Following the completion of the sale, the executive vice president now directly owns 978 shares in the company, valued at approximately $87,306.06. The trade was a 93.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 29,989 shares of company stock worth $2,702,261. Company insiders own 0.50% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently commented on BSX shares. Deutsche Bank Aktiengesellschaft raised shares of Boston Scientific from a “hold” rating to a “buy” rating and set a $108.00 price objective for the company in a research note on Friday, January 10th. Canaccord Genuity Group boosted their price target on Boston Scientific from $98.00 to $101.00 and gave the stock a “buy” rating in a research report on Monday, December 9th. Bank of America raised their price objective on Boston Scientific from $90.00 to $100.00 and gave the company a “buy” rating in a research report on Tuesday, October 22nd. StockNews.com upgraded shares of Boston Scientific from a “hold” rating to a “buy” rating in a report on Wednesday, January 29th. Finally, Piper Sandler raised their price target on shares of Boston Scientific from $95.00 to $115.00 and gave the company an “overweight” rating in a report on Monday. One equities research analyst has rated the stock with a hold rating, twenty-two have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $100.39.

Boston Scientific Trading Up 0.7 %

Boston Scientific stock opened at $103.11 on Tuesday. Boston Scientific Co. has a 52 week low of $64.08 and a 52 week high of $104.25. The stock has a 50-day moving average price of $93.47 and a 200 day moving average price of $86.33. The company has a quick ratio of 1.02, a current ratio of 1.48 and a debt-to-equity ratio of 0.44. The company has a market capitalization of $151.97 billion, a price-to-earnings ratio of 85.22, a price-to-earnings-growth ratio of 2.68 and a beta of 0.80.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.